SR One leads the $37.5m B round for the gene therapy company with existing corporate investor MedImmune Ventures also investing.
Applied Genetic Technologies Corp. (AGTC), a US-based biotechnology company that receives much of its technology licenced from the University of Florida, has raised a $37.5m series B round. GlaxoSmithKline’s venture unit SR One led the round along with life science venture firm Alta Partners. They were joined by new investor Osage University Partners, a venture…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.